Diagnosis  	Diagnosis  	 NNP	O
and  	and  	 CC	O
therapy  	therapy  	 NN	O
of  	of  	 IN	O
atherosclerosis  	atherosclerosis  	 NN	B-NP
through  	through  	 IN	O
molecular  	molecular  	 JJ	B-NP
biological  	biological  	 JJ	I-NP
approaches  	approaches  	 NNS	I-NP
possibility  	possibility  	 NN	O
of  	of  	 IN	O
HDL-targeting  	HDL-targeting  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
by  	by  	 IN	O
manipulation  	manipulation  	 NN	B-NP
of  	of  	 IN	O
micro  	micro  	 JJ	O
RNA-33  	RNA-33  	 NNP	B-NP
Elevated  	Elevated  	 NNP	I-NP
levels  	levels  	 NNS	I-NP
of  	of  	 IN	O
low-density  	low-density  	 NN	B-NP
lipoprotein  	lipoprotein  	 NN	I-NP
cholesterol  	cholesterol  	 NN	I-NP
( 	( 	 -LRB-	O
LDL-C 	LDL-C 	 NNP	B-NP
)  	)  	 -RRB-	O
increase  	increase  	 VB	O
the  	the  	 DT	O
risk  	risk  	 NN	O
of  	of  	 IN	O
coronary  	coronary  	 JJ	B-NP
heart  	heart  	 NN	I-NP
disease  	disease  	 NN	I-NP
( 	( 	 -LRB-	O
CHD 	CHD 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
statin  	statin  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
to  	to  	 TO	O
decrease  	decrease  	 VB	O
LDL-C  	LDL-C  	 JJ	B-NP
significantly  	significantly  	 RB	O
reduces  	reduces  	 VBZ	O
the  	the  	 DT	O
risk  	risk  	 NN	O
of  	of  	 IN	O
cardiovascular  	cardiovascular  	 JJ	B-NP
events 	events 	 NNS	I-NP
.  	.  	 .	O
Despite  	Despite  	 IN	O
the  	the  	 DT	O
effectiveness  	effectiveness  	 NN	O
of  	of  	 IN	O
statin  	statin  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
,  	,  	 ,	O
there  	there  	 EX	O
remains  	remains  	 VBZ	O
a  	a  	 DT	O
significant  	significant  	 JJ	O
residual  	residual  	 JJ	B-NP
cardiovascular  	cardiovascular  	 JJ	I-NP
risk 	risk 	 NN	I-NP
.  	.  	 .	O
A  	A  	 DT	O
low  	low  	 JJ	O
plasma  	plasma  	 JJ	B-NP
concentration  	concentration  	 NN	I-NP
of  	of  	 IN	I-NP
high-density  	high-density  	 JJ	I-NP
lipoprotein  	lipoprotein  	 JJ	I-NP
cholesterol  	cholesterol  	 NN	I-NP
( 	( 	 -LRB-	O
HDL-C 	HDL-C 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
an  	an  	 DT	O
increased  	increased  	 JJ	O
risk  	risk  	 NN	O
of  	of  	 IN	O
CHD 	CHD 	 NNP	B-NP
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
recent  	recent  	 JJ	O
clinical  	clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
aimed  	aimed  	 VBN	O
at  	at  	 IN	O
reducing  	reducing  	 VBG	O
the  	the  	 DT	O
CHD  	CHD  	 NNP	B-NP
risk  	risk  	 NN	I-NP
by  	by  	 IN	O
raising  	raising  	 VBG	B-NP
HDL-C  	HDL-C  	 JJ	I-NP
levels  	levels  	 NNS	I-NP
have  	have  	 VBP	O
not  	not  	 RB	O
shown  	shown  	 VBN	O
satisfactory  	satisfactory  	 JJ	B-NP
results 	results 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
becoming  	becoming  	 VBG	O
evident  	evident  	 JJ	O
that  	that  	 IN	O
a  	a  	 DT	O
functional  	functional  	 JJ	B-NP
HDL-C  	HDL-C  	 NN	I-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
more  	more  	 RBR	O
desirable  	desirable  	 JJ	O
target  	target  	 NN	O
than  	than  	 IN	O
simply  	simply  	 RB	O
elevating  	elevating  	 VB	O
its  	its  	 PRP$	O
level 	level 	 NN	O
.  	.  	 .	O
This  	This  	 DT	O
review  	review  	 NN	O
summarizes  	summarizes  	 VBD	O
the  	the  	 DT	O
function  	function  	 NN	O
of  	of  	 IN	O
HDL-C  	HDL-C  	 JJ	B-NP
in  	in  	 IN	O
reverse  	reverse  	 JJ	B-NP
cholesterol  	cholesterol  	 NN	I-NP
transfer  	transfer  	 NN	I-NP
from  	from  	 IN	O
peripheral  	peripheral  	 JJ	B-NP
tissue  	tissue  	 NN	I-NP
and  	and  	 CC	O
discusses  	discusses  	 VBG	O
the  	the  	 DT	O
latest  	latest  	 JJS	O
HDL-targeting  	HDL-targeting  	 JJ	B-NP
therapeutic  	therapeutic  	 JJ	I-NP
strategies  	strategies  	 NNS	I-NP
including  	including  	 VBG	O
the  	the  	 DT	O
manipulation  	manipulation  	 NN	B-NP
of  	of  	 IN	O
microRNAs 	microRNAs 	 JJ	O
.  	.  	 .	O
